Patents Examined by Yunsoo Kim
-
Patent number: 10881718Abstract: Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.Type: GrantFiled: March 17, 2016Date of Patent: January 5, 2021Assignee: The University of KansasInventors: Cory Berkland, Joshua Sestak, Teruna J. Siahaan
-
Patent number: 10875922Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.Type: GrantFiled: March 25, 2016Date of Patent: December 29, 2020Assignee: Genentech, Inc.Inventors: Ying Yang, Sreedhara Alavattam
-
Patent number: 10849977Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.Type: GrantFiled: February 23, 2018Date of Patent: December 1, 2020Assignee: EAGLE BIOLOGICS, INC.Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
-
Patent number: 10851150Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.Type: GrantFiled: July 24, 2018Date of Patent: December 1, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
-
Patent number: 10835602Abstract: The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.Type: GrantFiled: October 31, 2017Date of Patent: November 17, 2020Assignee: Novo Nordisk A/SInventors: Henrik Parshad, Dorthe Kot Engelund
-
Patent number: 10828351Abstract: A liposomal vaccine composition comprises a ?-amyloid (A?)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.Type: GrantFiled: April 9, 2019Date of Patent: November 10, 2020Assignee: AC Immune SAInventors: Emma Fiorini, Marija Vukicevic Verhille, Maria Pihlgren Bosch
-
Patent number: 10821184Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.Type: GrantFiled: February 6, 2018Date of Patent: November 3, 2020Assignee: Eagle Biologics, Inc.Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
-
Patent number: 10821183Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.Type: GrantFiled: November 10, 2017Date of Patent: November 3, 2020Assignee: Eagle Biologics, Inc.Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
-
Patent number: 10808021Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.Type: GrantFiled: July 24, 2018Date of Patent: October 20, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
-
Patent number: 10799585Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: June 29, 2018Date of Patent: October 13, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10792359Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: January 19, 2018Date of Patent: October 6, 2020Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Patent number: 10786567Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.Type: GrantFiled: September 14, 2016Date of Patent: September 29, 2020Assignees: Suzhou Suncediabiopharmaeuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
-
Patent number: 10786566Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: August 15, 2017Date of Patent: September 29, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10780163Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: July 18, 2017Date of Patent: September 22, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10772959Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10772960Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10765736Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: November 28, 2017Date of Patent: September 8, 2020Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Patent number: 10752696Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.Type: GrantFiled: June 24, 2019Date of Patent: August 25, 2020Assignee: GENENTECH, INC.Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
-
Patent number: 10753934Abstract: The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate.Type: GrantFiled: February 1, 2018Date of Patent: August 25, 2020Assignee: Meso Scale Technologies, LLC.Inventors: Michael Tsionsky, Eli N. Glezer, Selen Stromgren, George Sigal, Jonathan K. Leland, Mark A. Billadeau, Svetlana Leytner, Mark Martin, Larry Helms
-
Patent number: 10722579Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: November 1, 2018Date of Patent: July 28, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne